{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:30:07Z","timestamp":1792726207781,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The introduction of pertuzumab has greatly improved pathological complete response (pCR) rates in HER2-positive breast cancer, yet effects on long-term survival have been limited and it is uncertain which patients derive most benefit. In this study, we determine the prognostic value of BluePrint subtyping in HER2-positive breast cancer. Additionally, we evaluate its use as a biomarker for predicting response to trastuzumab-containing neoadjuvant chemotherapy with or without pertuzumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>From a cohort of patients with stage II-III HER2-positive breast cancer who were treated with neoadjuvant chemotherapy and trastuzumab with or without pertuzumab, 836 patients were selected for microarray gene expression analysis, followed by readout of BluePrint standard (HER2, Basal and Luminal) and dual subtypes (HER2-single, Basal-single, Luminal-single, HER2-Basal, Luminal-HER2, Luminal-HER2-Basal). The associations between subtypes and pathological complete response (pCR), overall survival (OS) and breast cancer-specific survival (BCSS) were assessed, and pertuzumab benefit was evaluated within the BluePrint subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>BluePrint results were available for 719 patients. In patients with HER2-type tumors, the pCR rate was 71.9% in patients who received pertuzumab versus 43.5% in patients who did not (adjusted Odds Ratio 3.43, 95% CI 2.36\u20134.96). Additionally, a significantly decreased hazard was observed for both OS (adjusted hazard ratio [aHR] 0.45, 95% CI 0.25\u20130.80) and BCSS (aHR 0.46, 95% CI 0.24\u20130.86) with pertuzumab treatment. Findings were similar in the HER2-single subgroup. No significant benefit of pertuzumab was seen in other subtypes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with HER2-type or HER2-single-type tumors, pertuzumab significantly improved the pCR rate and decreased the risk of breast cancer mortality, which was not observed in other subtypes. BluePrint subtyping may be valuable in future studies to identify patients that are likely to be highly sensitive to HER2-targeting agents.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-023-01664-x","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T14:02:30Z","timestamp":1687183350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"M. C.","family":"Liefaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van der Voort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"van Ramshorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Horlings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kleijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mittempergher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Kuilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Glas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. H.","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"issue":"1","key":"1664_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25\u201332.","journal-title":"Lancet Oncol"},{"issue":"9","key":"1664_CR2","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384.","journal-title":"Ann Oncol"},{"issue":"12","key":"1664_CR3","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentje VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630\u201340.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1664_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791\u2013800.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1664_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122\u201331.","journal-title":"N Engl J Med"},{"key":"1664_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer. 2018;89:27\u201335.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1664_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jval.2018.11.014","volume":"22","author":"LP Garrison Jr","year":"2019","unstructured":"Garrison LP Jr, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States. Value Health. 2019;22(4):408\u201315.","journal-title":"Value Health"},{"issue":"13","key":"1664_CR8","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years\u2019 Follow-Up. J Clin Oncol. 2021;39(13):1448\u201357.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1664_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","volume":"22","author":"JM Perez-Garcia","year":"2021","unstructured":"Perez-Garcia JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, et al. Chemotherapy de-escalation using an (18)F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 2021;22(6):858\u201371.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1664_CR10","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1200\/JCO.21.00280","volume":"39","author":"RM Connolly","year":"2021","unstructured":"Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, et al. Updated results of TBCRC026: phase II trial correlating standardized uptake value with pathological complete response to pertuzumab and trastuzumab in breast cancer. J Clin Oncol. 2021;39(20):2247\u201356.","journal-title":"J Clin Oncol"},{"key":"1664_CR11","doi-asserted-by":"crossref","unstructured":"Gluz O, Nitz U, Christgen M, Kuemmel S, Holtschmidt J, Priel J, et al. De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+\/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study. Journal of Clinical Oncology. 2020;38(15_suppl):515.","DOI":"10.1200\/JCO.2020.38.15_suppl.515"},{"issue":"Suppl 1","key":"1664_CR12","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.breast.2017.06.022","volume":"34","author":"J Veeraraghavan","year":"2017","unstructured":"Veeraraghavan J, De Angelis C, Reis-Filho JS, Pascual T, Prat A, Rimawi MF, et al. De-escalation of treatment in HER2-positive breast cancer: determinants of response and mechanisms of resistance. Breast. 2017;34(Suppl 1):S19\u201326.","journal-title":"Breast"},{"key":"1664_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini F, Pascual T, Conte B, Chic N, Braso-Maristany F, Galvan P, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84: 101965.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1664_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10549-011-1683-z","volume":"133","author":"O Krijgsman","year":"2012","unstructured":"Krijgsman O, Roepman P, Zwart W, Carroll JS, Tian S, de Snoo FA, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012;133(1):37\u201347.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1664_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-022-06698-x","volume":"195","author":"MM Kuilman","year":"2022","unstructured":"Kuilman MM, Ellappalayam A, Barcaru A, Haan JC, Bhaskaran R, Wehkamp D, et al. BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance. Breast Cancer Res Treat. 2022;195(3):263\u201374.","journal-title":"Breast Cancer Res Treat"},{"key":"1664_CR16","doi-asserted-by":"crossref","unstructured":"Krop I, Mittempergher L, Paulson J, Andre F, Bonnefoi H, Loi S, et al. Abstract PD3-01: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: A biomarker analysis of the APHINITY trial. Cancer Res. 2021; 81(4 Suppl):PD3-01-PD3.","DOI":"10.1158\/1538-7445.SABCS20-PD3-01"},{"issue":"7","key":"1664_CR17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","volume":"7","author":"A van der Voort","year":"2021","unstructured":"van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7(7):978\u201384.","journal-title":"JAMA Oncol"},{"key":"1664_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.breast.2016.07.017","volume":"29","author":"MS van Ramshorst","year":"2016","unstructured":"van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentje VO, Oving IM, Mandjes IA, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast. 2016;29:153\u20139.","journal-title":"Breast"},{"issue":"1","key":"1664_CR19","first-page":"19","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19\u201324.","journal-title":"Cell Oncol"},{"key":"1664_CR20","unstructured":"Slide Score. Available from: https:\/\/www.slidescore.com."},{"key":"1664_CR21","unstructured":"Nationaal Borstkanker Overleg Nederland. Dutch Guideline Breast Cancer 2012 [Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/algemeen.html."},{"issue":"31","key":"1664_CR22","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997\u20134013.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1664_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"D Ho","year":"2011","unstructured":"Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J Stat Softw. 2011;42(8):1\u201328.","journal-title":"J Stat Softw"},{"issue":"4","key":"1664_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100756","volume":"13","author":"L Mittempergher","year":"2020","unstructured":"Mittempergher L, Delahaye LJ, Witteveen AT, Snel MH, Mee S, Chan BY, et al. Performance characteristics of the BluePrint(R) breast cancer diagnostic test. Transl Oncol. 2020;13(4): 100756.","journal-title":"Transl Oncol"},{"key":"1664_CR25","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/S0959-8049(20)30821-2","volume":"138","author":"A Ellappalayam","year":"2020","unstructured":"Ellappalayam A, Kuilman M, Mittempergher L, Wehkamp D, Chan B, Bhaskaran R, et al. 518 Poster\u2013BluePrint molecular subtyping recognizes single and dual subtype tumors with consequences for therapeutic guidance. Eur J Cancer. 2020;138:S106\u20137.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1664_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"key":"1664_CR27","unstructured":"R Core Team. R: A language and environment for statistical computing: R Foundation for Statistical Computing, Vienna, Austria.; 2022 https:\/\/www.R-project.org\/."},{"key":"1664_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00197","volume":"6","author":"PW Whitworth","year":"2022","unstructured":"Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, et al. Genomic classification of HER2-positive patients with 80-gene and 70-gene signatures identifies diversity in clinical outcomes With HER2-targeted neoadjuvant therapy. JCO Precis Oncol. 2022;6: e2200197.","journal-title":"JCO Precis Oncol"},{"issue":"24","key":"1664_CR29","doi-asserted-by":"publisher","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","volume":"69","author":"W Scheuer","year":"2009","unstructured":"Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330\u20136.","journal-title":"Cancer Res"},{"issue":"7","key":"1664_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/19420862.2016.1204503","volume":"8","author":"G Toth","year":"2016","unstructured":"Toth G, Szoor A, Simon L, Yarden Y, Szollosi J, Vereb G. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. MAbs. 2016;8(7):1361\u201370.","journal-title":"MAbs"},{"issue":"8","key":"1664_CR31","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1664_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"10","key":"1664_CR33","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674.","journal-title":"Ann Oncol"},{"issue":"7","key":"1664_CR34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321.","journal-title":"N Engl J Med"},{"key":"1664_CR35","doi-asserted-by":"crossref","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022.","DOI":"10.1056\/NEJMoa2203690"},{"key":"1664_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.breast.2022.07.005","volume":"65","author":"A van der Voort","year":"2022","unstructured":"van der Voort A, Liefaard MC, van Ramshorst MS, van Werkhoven E, Sanders J, Wesseling J, et al. Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival. The Breast. 2022;65:110\u20135.","journal-title":"The Breast"},{"issue":"14","key":"1664_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273\u201383.","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01664-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-023-01664-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01664-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T14:06:58Z","timestamp":1687183618000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-023-01664-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1186\/s13058-023-01664-x","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Research Board of the Netherlands Cancer Institute (CFMPB672). In addition, the review board of the Netherlands Cancer Registry and Statistics Netherlands approved this study and it was conducted in accordance with the Declaration of Helsinki. The TRAIN-2 clinical trial was approved by the medical ethics committee of the Netherlands Cancer Institute, and all participants signed written informed consent before any study-related procedure.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.S.S. reports institutional research support from Agendia, AstraZeneca, Merck, Novartis, Roche and Seagen and consultancy fees paid to the institute from Biovica and Seagen. H.M.H. reports institutional research support from Roche. M.K., L.M, M.M.K. and A.M.G. are employees of Agendia NV. All other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}